Gewinn- und Verlustrechnung von ResMed Inc.

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

ResMed (NYSE: RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care. Chairman and Chief Executive Officer Mick Farrell said the company has issued guidance for 5% to 7% core constant-currency revenue growth, including an

ResMed NYSE: RMD outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care.

Engineers Gate Manager LP raised its stake in ResMed Inc. (NYSE: RMD) by 77.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,127 shares of the medical equipment provider's stock after acquiring an additional 3,555 shares during the period. Engineers Gate

Setbacks for competitors have positioned ResMed to capture more market share.

AI regulation odds have sharply declined after Trump dismissed AI takeover concerns during a public call with Nvidia (NVDA) CEO Jensen Huang. ResMed (RMD) was upgraded to Outperform by RBC Capital Markets, with a price target raised to $262, citing strong Q4 results and expected high-single-digit EPS growth.

ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.

Markets are rattled ahead of Wednesday's Fed decision, and Wall Street analysts are making bold moves on names like Eli Lilly, Etsy, Northrop Grumman, and Rivian. Find out which stocks got upgraded, downgraded, or newly covered before the opening bell.

ResMed has de-rated from 30x to under 21x earnings despite 17% EPS growth, driven by narrative rather than fundamentals. Recurring mask and consumables revenue, now 42% of the sleep and breathing segment, is underappreciated and grew 13% last year. Two major risks—sleep apnea pill and reimbursement—are less material for RMD than feared; Philips' US return poses the most credible threat.